The global bispecific antibody therapeutics contract manufacturing market size is expected to reach USD 62.65 billion by 2030 and is projected to grow at a CAGR of 36.4% from 2023 to 2030. The bispecific antibodies (bsAB) represent a rapidly growing therapeutic approach with the emerging development of recombinant DNA technology and understanding of antibody engineering. These antibody therapeutics offer a range of therapeutic benefits to serve the unmet needs of patients. In addition, the therapeutic potential to treat cancer, diabetes, Alzheimer's, and ophthalmological diseases drive the market need. The abundant attention and investment in bispecific antibodies are the key factors for market growth.
Likewise, ongoing research activities in drug discovery, preclinical, and clinical stage studies, as well as numerous antibodies entering clinical development offer a promising future for patients suffering from various diseases that do not have many treatment options. For instance, according to WuXi Biologics, 100+ different bispecific formats are currently available, wherein approximately 160 bispecific antibodies are in clinical trials & 460 bispecific antibodies are in pre-clinical development. The rising number of clinical trials is expected to lead the way in antibody-based therapeutics. In addition, the rapid success of bispecific antibody therapeutics in cancer and non-cancer programs has boosted the demand for the market. With the growing burden of cancer, bispecific antibody therapeutics have gained success in the treatment of various cancer diseases.
For instance, according to Sino Biological Inc., more than 85% of bispecific antibodies in clinical trials are cancer therapeutics. Similarly, as of 2022, a total of six bsAbs have received approval by EMA and FDA in cancer immunotherapy including the initially approved bsAb, Catumaxomab. The COVID-19 pandemic has positively impacted the growth of the bispecific antibody therapeutics contract manufacturing industry. The increasing research and development activities and pre-clinical trials for bispecific antibodies have certainly shown the potential to neutralize SARS-CoV-2 and its variants. Besides, the high bispecific potency and overall characteristics of bsAbs make it an ideal choice for clinical trials further supporting for prevention and treatment of COVID-19. Furthermore, the key participants are engaged in strategies, such as bispecific antibody therapeutics approvals, partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio.
For instance, in August 2022, the European Commission granted Janssen Pharmaceutical Companies of Johnson & Johnson company’s TECVAYLI (teclistamab) with conditional marketing authorization. TECVAYLI (teclistamab) is a monotherapy for the treatment of adult patients with relapsed & refractory multiple myeloma. In addition, in October 2022, the FDA granted accelerated approval to Tecvayli. Similarly, in June 2022, the European Commission granted Roche company’s CD20xCD3 T-cell binding bispecific antibody Lunsumio (mosunetuzumab) a conditional marketing authorization. It will be used for the treatment of follicular lymphoma, relapsed or refractory, in patients who have received prior two systemic therapies.
This product will be delivered within 1-3 business days.
Likewise, ongoing research activities in drug discovery, preclinical, and clinical stage studies, as well as numerous antibodies entering clinical development offer a promising future for patients suffering from various diseases that do not have many treatment options. For instance, according to WuXi Biologics, 100+ different bispecific formats are currently available, wherein approximately 160 bispecific antibodies are in clinical trials & 460 bispecific antibodies are in pre-clinical development. The rising number of clinical trials is expected to lead the way in antibody-based therapeutics. In addition, the rapid success of bispecific antibody therapeutics in cancer and non-cancer programs has boosted the demand for the market. With the growing burden of cancer, bispecific antibody therapeutics have gained success in the treatment of various cancer diseases.
For instance, according to Sino Biological Inc., more than 85% of bispecific antibodies in clinical trials are cancer therapeutics. Similarly, as of 2022, a total of six bsAbs have received approval by EMA and FDA in cancer immunotherapy including the initially approved bsAb, Catumaxomab. The COVID-19 pandemic has positively impacted the growth of the bispecific antibody therapeutics contract manufacturing industry. The increasing research and development activities and pre-clinical trials for bispecific antibodies have certainly shown the potential to neutralize SARS-CoV-2 and its variants. Besides, the high bispecific potency and overall characteristics of bsAbs make it an ideal choice for clinical trials further supporting for prevention and treatment of COVID-19. Furthermore, the key participants are engaged in strategies, such as bispecific antibody therapeutics approvals, partnerships, agreements, collaborations, and launches, to expand their global footprints and product portfolio.
For instance, in August 2022, the European Commission granted Janssen Pharmaceutical Companies of Johnson & Johnson company’s TECVAYLI (teclistamab) with conditional marketing authorization. TECVAYLI (teclistamab) is a monotherapy for the treatment of adult patients with relapsed & refractory multiple myeloma. In addition, in October 2022, the FDA granted accelerated approval to Tecvayli. Similarly, in June 2022, the European Commission granted Roche company’s CD20xCD3 T-cell binding bispecific antibody Lunsumio (mosunetuzumab) a conditional marketing authorization. It will be used for the treatment of follicular lymphoma, relapsed or refractory, in patients who have received prior two systemic therapies.
Bispecific Antibody Therapeutics Contract Manufacturing Market Report Highlights
- Based on indication, the cancer segment held the largest revenue share of 55.7% in 2022. The immense demand for bispecific antibody therapeutics drives the segment. In addition, the market for antibody therapeutics has become an attractive choice to treat cancer, due to its safety and efficacy profile
- Based on the route of administration, the intravenous segment held the largest share of 45.2% in 2022, owing to its advantages in recovery. These antibodies not only efficiently recruit the endogenous bone marrow stem cells, but also support the cell's target
- In terms of end-use, the biopharmaceutical companies segment is anticipated to register the fastest CAGR of 37.1% from 2023 to 2030. This is due to the high burden of cancer, increasing demand for advanced antibody therapies, a growing number of clinical trials, rising R&D activities, and investments
- North America held the largest revenue share of 69.7% in 2022. The presence of well-established market players, increasing burden of cancer & other diseases, growing research activities, rising number of clinical trials, and investments are driving the regional market growth
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology And Scope
Chapter 2. Executive Summary
Chapter 3. Bispecific Antibody Therapeutics Contract Manufacturing Market Variables, Trends & Scope
Chapter 4. Bispecific Antibody Therapeutics Contract Manufacturing Market: Indication Estimates & Trend Analysis
Chapter 5. Bispecific Antibody Therapeutics Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis
Chapter 6. Bispecific Antibody Therapeutics Contract Manufacturing Market: End-use Estimates & Trend Analysis
Chapter 7. Bispecific Antibody Therapeutics Contract Manufacturing Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Lonza
- Roche's
- Creative Biolabs
- AbbVie
- Amgen
- Janssen
- Johnson & Johnson
- IQVIA
- WuXi Biologics
- Sino Biological Inc
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | August 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 5.29 Billion |
| Forecasted Market Value ( USD | $ 62.65 Billion |
| Compound Annual Growth Rate | 36.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
